MXPA01012882A - Composiciones y metodos que comprenden gluconato de morfina. - Google Patents

Composiciones y metodos que comprenden gluconato de morfina.

Info

Publication number
MXPA01012882A
MXPA01012882A MXPA01012882A MXPA01012882A MXPA01012882A MX PA01012882 A MXPA01012882 A MX PA01012882A MX PA01012882 A MXPA01012882 A MX PA01012882A MX PA01012882 A MXPA01012882 A MX PA01012882A MX PA01012882 A MXPA01012882 A MX PA01012882A
Authority
MX
Mexico
Prior art keywords
gluconate
morphine
present
compositions
methods
Prior art date
Application number
MXPA01012882A
Other languages
English (en)
Inventor
Charanjit R Behl
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of MXPA01012882A publication Critical patent/MXPA01012882A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Abstract

La presente invencion se relaciona con una composicion farmacéutica que incluye gluconato de morfina o un equivalente químico del mismo. En una realizacion, la presente invencion incluye un método de preparacion de gluconato de morfina o de un equivalente químico de éste mezclando sulfato de morfina con gluconato de sodio. La presente invencion incluye también un método para provocar una respuesta analgésica o anestésica en un mamífero, que incluye la administracion de una cantidad terapéuticamente efectiva de una composicion farmacéutica que incluye gluconato de morfina o un equivalente químico del mismo.
MXPA01012882A 1999-06-16 2000-05-23 Composiciones y metodos que comprenden gluconato de morfina. MXPA01012882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/334,344 US6225343B1 (en) 1999-06-16 1999-06-16 Compositions and methods comprising morphine gluconate
PCT/US2000/014150 WO2000076314A1 (en) 1999-06-16 2000-05-23 Compositions and methods comprising morphine gluconate

Publications (1)

Publication Number Publication Date
MXPA01012882A true MXPA01012882A (es) 2003-06-24

Family

ID=23306791

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01012882A MXPA01012882A (es) 1999-06-16 2000-05-23 Composiciones y metodos que comprenden gluconato de morfina.

Country Status (10)

Country Link
US (2) US6225343B1 (es)
EP (1) EP1185171A4 (es)
JP (1) JP2003501446A (es)
KR (1) KR20020016832A (es)
AU (1) AU775112B2 (es)
BR (1) BR0012081A (es)
CA (1) CA2376865A1 (es)
MX (1) MXPA01012882A (es)
NZ (1) NZ515781A (es)
WO (1) WO2000076314A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
WO2004092189A1 (en) * 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
JP2006522834A (ja) * 2003-04-09 2006-10-05 ワイス ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の鼻腔内投与用医薬組成物およびその使用法
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ES2660172T3 (es) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
BRPI0807290A2 (pt) 2007-03-02 2016-10-11 Teika Pharmaceutical Co Ltd "composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma"
EP2131828A2 (en) * 2007-03-05 2009-12-16 Eisai R&D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
JP2010524844A (ja) * 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 認知症のためのシンナミド化合物
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
BRPI0815821A2 (pt) * 2007-08-27 2015-02-18 Wyeth Llc Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US9730472B2 (en) * 2013-09-30 2017-08-15 Darrin B. Farrow Vaporization device and method of preparation and use
KR20220002950A (ko) 2019-05-01 2022-01-07 클렉시오 바이오사이언시스 리미티드 소양증의 치료 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE706059C (de) * 1935-04-02 1941-05-16 Jean Lucien Regnier Verfahren zur Herstellung von Salzen der Opiumalkaloide, insbesondere des Morphins
US2312440A (en) * 1935-04-02 1943-03-02 Regnier Jean Lucien Alkaloid salts and the manufacture thereof
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5198209A (en) 1992-02-11 1993-03-30 Amway Corporation Conditioning shampoo
ATE241984T1 (de) * 1993-03-26 2003-06-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin
WO1996003976A1 (en) * 1994-08-01 1996-02-15 Kv Pharmaceutical Corporation Tastemasked liquid pharmaceutical delivery system
GB9426103D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
GB9505491D0 (en) 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9513117D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
WO2000076507A1 (en) * 1999-06-16 2000-12-21 Nastech Pharmaceutical Company, Inc. Method for increasing the solubility of morphine and pharmaceutical compositions prepared therefrom

Also Published As

Publication number Publication date
US6451848B1 (en) 2002-09-17
BR0012081A (pt) 2002-04-02
EP1185171A4 (en) 2004-09-29
EP1185171A1 (en) 2002-03-13
CA2376865A1 (en) 2000-12-21
AU775112B2 (en) 2004-07-15
NZ515781A (en) 2004-01-30
AU5040500A (en) 2001-01-02
KR20020016832A (ko) 2002-03-06
WO2000076314A1 (en) 2000-12-21
US6225343B1 (en) 2001-05-01
JP2003501446A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
MXPA01012882A (es) Composiciones y metodos que comprenden gluconato de morfina.
RU93043625A (ru) Композиция, включающая вещество трамадол и ацетаминофен, и способ лечения с ее использованием
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
MXPA03005394A (es) Composiciones que contienen complejos de inclusion.
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
WO2005027895A3 (en) Thyroid hormone analogs and methods of use in angiogenesis
SG152257A1 (en) Topical preparation containing ambroxol
DK1427297T3 (da) Appetitnedsættende procyanidin-holdigt præparat til pattedyr
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
GB9917822D0 (en) Nmda antagonist
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
IL166596A0 (en) Salt of morphine-6-glucoronide
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
NZ523606A (en) Pharmaceutical compositions and methods for use
EP1303520A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
ATE287265T1 (de) Verwendung von schwachen opioiden und gemischten opioidagonisten / -antagonisten zur therapie der harninkontinenz
BR0005319A (pt) Tratamento combinado para depressão e ansiedade

Legal Events

Date Code Title Description
FA Abandonment or withdrawal